タカダ タクマ   TAKADA Takuma
  髙田 卓磨
   所属   研究施設 研究施設
   職種   非常勤講師
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Neoatherosclerosis 5 Years After Bioresorbable Vascular Scaffold Implantation.
掲載誌名 正式名:Journal of the American College of Cardiology
略  称:J Am Coll Cardiol
ISSNコード:15583597/07351097
掲載区分国外
巻・号・頁 71(17),pp.1882-1893
著者・共著者 Moriyama Noriaki, Shishido Koki, Tanaka Yutaka, Yokota Shohei, Hayashi Takahiro, Miyashita Hirokazu, Koike Tatsuya, Yokoyama Hiroaki, Takada Takuma, Nishimoto Takashi, Ochiai Tomoki, Tobita Kazuki, Yamanaka Futoshi, Mizuno Shingo, Murakami Masato, Takahashi Saeko, Saito Shigeru
発行年月 2018/05
概要 BACKGROUND:Data regarding neoatherosclerosis after everolimus-eluting bioresorbable vascular scaffold (BVS) (ABSORB BVS Rev. 1.1, Abbott Vascular, Santa Clara, California) implantation are limited.OBJECTIVES:This study investigated the findings of neoatherosclerosis at 5 years after BVS 1.1 implantation by using multi-imaging modalities, including optical coherence tomography (OCT).METHODS:Patients included in the ABSORB EXTEND (ABSORB EXTEND Clinical Investigation) trial at Shonan Kamakura General Hospital underwent OCT at baseline after the index procedure and at 1 and 5 years. Intimal plaque distributions in the in-scaffold and out-scaffold segments were analyzed.RESULTS:Twenty patients (22 lesions) with stable angina pectoris were enrolled. The median follow-up duration was 67 months (interquartile range: 65 to 69 months), and the mean age was 69 ± 8 years. Patients with diabetes mellitus (25%) were included. Based on the baseline angiogram, 10 (46%) lesions were type B2/C lesions. At 1 and 5 years of follow-up, significant differences in the prevalence of in-scaffold lipid-laden neointima (17% vs. 61%; p = 0.04), calcification (28% vs. 94%; p < 0.01), neovascularization (6% vs. 78%; p < 0.01), and thin-cap fibroatheroma (0% vs. 22%; p = 0.02) were found. In the out-scaffold segments, no significant difference in the plaque prevalence between 1 and 5 years was noted.CONCLUSIONS:The occurrence and progression of in-scaffold neoatherosclerosis with luminal narrowing was observed at 5 years after BVS 1.1 implantation. The small size of the current study warrants confirmation in larger study. (ABSORB EXTEND Clinical Investigation [ABSORB EXTEND]; NCT01023789).
DOI 10.1016/j.jacc.2018.02.051
PMID 29699614